J&J Talks Up Wellness As Economy, Generics Shadow ’09
Executive Summary
Johnson & Johnson CEO William Weldon emphasized the company's emerging wellness and prevention strategy during a year-end sales and earnings presentation Jan. 20, in which the macroeconomic climate, loss of Risperdal and declining sales of Procrit weighed on the pharmaceutical segment's top line
You may also be interested in...
Merck’s Ambitious Plans For Follow-On Biologics
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.